
ANTX Stock Forecast & Price Target
ANTX Analyst Ratings
Bulls say
AN2 Therapeutics Inc. has demonstrated significant promise in its drug development pipeline, particularly with AN2-502998, which achieved 100% survival in non-human primate models for Chagas disease, surpassing previously developed agents from established pharmaceutical companies. The recognition of unmet medical needs in diseases such as Chagas and melioidosis further enhances the strategic importance of AN2's therapeutic candidates. Although additional safety data from human trials is required for comprehensive valuation, the company's innovative boron-based compounds and positive preclinical results point toward a favorable long-term outlook for AN2 Therapeutics's stock.
Bears say
AN2 Therapeutics Inc has a persistent history of financial losses and lacks a proven track record of profitability, raising concerns about its long-term viability. The company's ability to successfully partner for favorable terms is uncertain, which could jeopardize the success of any potential commercial launch. Additionally, the risks associated with the efficacy and safety of its drug candidates in clinical development could hinder approval and commercialization efforts, further complicating its financial outlook.
This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ANTX Analyst Forecast & Price Prediction
Start investing in ANTX
Order type
Buy in
Order amount
Est. shares
0 shares